[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepatitis-c-virus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepatitis-c-virus-infection":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,75,106,127,154,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100582953","hepatitis-c-tracker-study-100582953",false,"NCT06870019","Hepatitis C Tracker Study","Effects of GPS Tracking on Patient Adherence to Hepatitis C Treatment Among People Experiencing Unsheltered Homelessness","Inclusion Criteria:\n\n* Diagnosed with Hepatitis C infection\n* Experiencing unsheltered homelessness at study initiation\n* Speaks English or Spanish\n* Receiving street medicine care\n* Meet the American Association for the Study of Liver Diseases (AASLD) criteria for simplified treatment of Hepatitis C\n\nExclusion Criteria:\n\n* Prior engagement in HCV treatment\n* Decompensated cirrhosis; HBsAg positive\n* Current pregnancy; Known or suspended hepatocellular carcinoma\n* Prior liver transplantation","ALL","18 Years",{"count":19,"type":20},124,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this study is to determine if GPS tracking can enhance adherence to hepatitis C treatment among patients diagnosed with hepatitis C infection who are also experiencing unsheltered homelessness and receiving street medicine. Research will compare medication adherence among participants randomly assigned to receive standard medical care for Hepatitis C versus the standard medical care for Hepatitis C along with GPS tracking assistance.",[26],"Hepatitis C Virus Infection",[28,29,30,31,32,33],"Street medicine","Unsheltered homelessness","Hepatitis C","GPS tracker","Mixed-methods","Ill-housed person","RECRUITING","2025-08-22",{"date":37,"type":38},"2025-08-29","ACTUAL",{"date":40,"type":38},"2025-08-08",{"date":42,"type":20},"2027-12-31",{"name":44,"class":45},"University of Southern California","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100600514","phase-4-access-to-hepatitis-c-treatment-in-cameroon-comparison-of-a-simplified-test-and-treat-strategy-to-a-standard-strategy-100600514","NCT07098481","Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy","ACCESS+","Inclusion Criteria:\n\n* Persons of both genders aged 21 years or older\n* Anti-HCV positive;\n* Living in the study area\n* Agreeing to participate in the trial and signing the informed consent form.\n\nExclusion Criteria:\n\n* Participationin a previous study on HCV treatment\n* Previous sofosbuvir treatment\n* HBsAg positive or indeterminate;\n* Pregnancy test positive ;\n* Life-threatening condition ;\n* Impairment of the person making it difficult, if not impossible, for them to participate in the trial or to understand the information given to them.","21 Years",{"count":56,"type":20},576,[58],"PHASE4","Hepatitis C is a common and potentially serious disease. However, there are treatments that can cure it. That's why it's so important to detect the hepatitis C virus (HCV) and treat those affected. Today, many hepatitis C sufferers in Cameroon (and elsewhere) remain untreated.\n\nThe aim of this research is therefore to evaluate a simplified screening and treatment strategy (developed specifically for the Cameroonian context) in comparison with a standard strategy (based on usual care), in order to improve access to hepatitis C treatment in Cameroon. If the results of this research are positive, this strategy could be recommended to health authorities in Cameroon and other comparable countries.",[26],[62,63],"simplified test and treat strategy","hepatitis C","NOT_YET_RECRUITING","2025-07-31",{"date":67,"type":38},"2025-08-01",{"date":69,"type":20},"2025-09-01",{"date":71,"type":20},"2028-06-30",{"name":73,"class":74},"ANRS, Emerging Infectious Diseases","OTHER_GOV",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":85,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100549279","early-detection-of-hcv-in-injection-drug-users-100549279","NCT06431945","Early Detection of HCV in Injection Drug Users","Early Detection of Hepatitis C in Injection Drug Users","EDVIP","Inclusion Criteria:\n\n* age 18+\n* an active injecting drug user or have used injecting drugs at any time in the past\n\nExclusion Criteria:\n\n* not agreeing to participate in the project",{"count":84,"type":20},3000,"2 Months","OBSERVATIONAL","The project is a national, prospective, multicenter, non-interventional pilot project of screening HCV in PWID in the Czech Republic.\n\nThe main goal of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of Hepatitis C and setting up and testing new methods and implementation into the system of social health care.",[26],[90,91,92,93,94,95],"HCV","PWID","Point of care testing","Hepatitis","Czech Republic","HCV genotype","2025-06-25",{"date":98,"type":38},"2025-06-29",{"date":100,"type":38},"2023-12-15",{"date":102,"type":20},"2025-12-31",{"name":104,"class":74},"Institute of Health Information and Statistics of the Czech Republic",18,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100571305","characterization-of-immune-genotypes-and-antibody-profiles-to-foster-the-discovery-of-diagnosticbiomarkers-of-liver-cancer-development-100571305","NCT06718530","Characterization of Immune Genotypes and Antibody Profiles to Foster the discoVERY of diagnosticbioMARKERS of Liver Cancer Development","VERYMARKERS","Inclusion Criteria:\n\n* Patients aged ≥18 years with the presence of chronic infection, fibrosis, cirrhosis or HCV- associated HCC\n* Patients able to understand and willing to sign the of informed consent\n* Patients to answer the questions in the questionnaire of enrollment\n\nExclusion Criteria:\n\n* Treatment for other oncological diseases\n* Immunodepression congenital or acquired (HIV, organ transplantation, pharmacological)",{"count":114,"type":20},1000,"Hepatitis C virus (HCV), which infects more than 185 million people, is a major risk factor. Direct-acting antiviral (DAA) therapy has significantly improved the eradication of the virus, but has not completely eliminated the risk of HCC, so careful surveillance is necessary. The genetic diversity of the natural killer receptor, histocompatibility antigens (HLA) and interferon lambda 4 (INFL4) activity, among other factors, have been found to be crucial in directing disease progression. Importantly, these markers are detectable years before the diagnosis of HCC. In addition, polymorphic variants attributable to the expression of genes involved in innate-type immune response, such as IFNL4 and HLA-E, have been shown to be predictive for the development of HCC and have not yet been extensively studied. The aim of the study is to evaluate novel circulating biomarkers, including the presence of antibodies to specific HCV proteome peptides, IFNL4 expression, and the interaction of specific HLA receptors\u002Fligands in a large cohort of HCV-positive subjects in order to create a screening strategy for the early diagnosis of HCV-associated HCC.\n\nPart of the study will be devoted to describing the immune microenvironment associated with the expression of IFNL4 and HLAE, evaluating them as potential prognostic indicators for HCC in HCV-infected subjects undergoing surgery for HCC, as well as in those with advanced\u002Fmetastatic HCC.",[26],"2024-12-02",{"date":119,"type":38},"2024-12-05",{"date":121,"type":38},"2024-05-13",{"date":123,"type":20},"2026-12-31",{"name":125,"class":45},"Centro di Riferimento Oncologico - Aviano",4,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":134,"sex":16,"minAge":135,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100444732","screening-treatment-and-eradication-of-hep-c-100444732","NCT05071261","Screening, Treatment, and Eradication of Hep C","A Communication-Based Study Focused on Assessing and Improving Hepatitis C Screening Rates, As Well As Treatment Rates in Arizona as a Step Towards Disease Eradication","Inclusion Criteria:\n\n* Subjects must sign the consent to screen and take part in the study.\n* Subjects must be at least 15 years of age\n\nExclusion Criteria:\n\n* Patients will only be enrolled once\n* Patients who do not meet the inclusion criteria\n* Patients with a current HCV diagnosis\n* Patients who underwent a liver transplant",true,"15 Years",{"count":137,"type":20},112136,"The aim of this study is to assess the HCV screening rate in Arizona by identification of potential HCV patients\u002Fsubjects through different methods of communication - text message, email, social media, radio, newspaper ads, and flyers.",[26],[141,142,143,144],"Liver","Hepatitis C Virus","Screening","Disease Eradication","2024-08-26",{"date":147,"type":38},"2024-08-27",{"date":149,"type":20},"2024-09-01",{"date":151,"type":20},"2030-12-01",{"name":153,"class":45},"Liver Institute PLLC",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":134,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100551732","screening-for-hepatitis-c-in-people-who-inject-drugs-in-armenia-colombia-100551732","NCT06463912","Screening for Hepatitis c in People Who Inject Drugs in Armenia-Colombia","HCV-PIWD","Inclusion Criteria:\n\n* Be between 18 and 65 years old.\n* Having used injected psychoactive substances in the last six months.\n* Residing in the city or metropolitan area of study in the last six months.\n* Present the invitation coupon.\n* Person with Colombian nationality, Venezuelan migrant population.\n\nExclusion Criteria:\n\n* Person who, due to physical, cognitive, or limitations derived from the use of psychoactive substances, is not able to answer the survey autonomously.\n* Be in a state of consumption and is prevented from responding to the survey.\n* Refuses to collaborate in the study.","100 Years",{"count":163,"type":20},205,"Hepatitis C virus infection is a major cause of chronic hepatitis, cirrhosis, and liver cancer. The risk of developing cirrhosis for people with chronic infection with the virus ranges from 15% to 30% over 20 years. Despite undeniable advances in the treatment of hepatitis C infection and the WHO strategy to eliminate hepatitis C by 2030, this infection continues to be a major public health problem globally and many HCV-positive individuals are unaware of their HIV status. People who inject drugs (PWID) are at increased risk for HCV. Several studies have reported high HCV prevalence rates, especially among PWID. PWID are usually exposed to a higher risk of various infectious diseases, mainly due to their drug consumption behaviors and habits, in addition to the risks and harms associated with the respective routes of self-administration.\n\nWorldwide, there are around 11 million PWIDs and there are approximately 2.3 million coinfections between HIV and HCV worldwide, of which more than half (1.3 million) occur in PWID. The coexistence of these two health conditions leads to accelerate the progression of liver disease. The global prevalence of HCV in 2019 among PWID was 50.2%, which is equivalent to 5.6 million people who inject drugs and live with hepatitis C. PWID had been considered a difficult group to reach, manage, and treat because HCV treatment management in these individuals is challenging and they have a higher risk of reinfection and some past HCV treatment guidelines excluded PWIDs from consideration, citing concerns about adherence, increased susceptibility to side effects, and reinfection. However, there is now compelling evidence that HCV treatment is safe and effective among PWID.\n\nIn Colombia, the prevalence of hepatitis C among PWID has been measured locally in some cities. In Bogotá, it went from 1.7% in 2002 to 6.7% in 2014. For 2021, the prevalence of hepatitis C was measured in Bogotá, Medellín, Santiago de Cali, the metropolitan area of Pereira, Dos Quebradas, Medellín, Cucuta, and Armenia. The results of prevalence of antibodies against hepatitis C were as follows: Cali with 80.2%, is the city with the highest reactivity, followed by Pereira and Dos Quebradas with 71.4%, Armenia with 69.6%, and Cucuta with 62.8%. We do not have recent data about the impact of intervention to reduce HVC transmission in those groups.",[26],[167,168,169],"Hepatitis C chronic","Drug Use","Hepatitis C Antibodies rapid test","2024-06-14",{"date":172,"type":38},"2024-06-18",{"date":174,"type":38},"2024-05-20",{"date":176,"type":20},"2025-03-31",{"name":178,"class":45},"Asociación Colombiana de Hepatología",1,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":134,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":187,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":46},"100527995","adult-screening-for-hepatitis-c-and-linkage-to-treatment-in-hospitals-in-colombia-100527995","NCT06155006","Adult Screening for Hepatitis c and Linkage to Treatment in Hospitals in Colombia","HCVLINKAGE","Inclusion Criteria:\n\nHave at least one of the following risk factors for hepatitis C.\n\n* Over 50 years of age with no risk factors.\n* Over 18 years old and less than 50 years old with risk factors for hepatitis C. Persons who have received medical or dental interventions in health care settings.\n\nPersons who have had tattoos, body piercings, or scarification procedures. Persons with HIV or hepatitis B infection. Persons who inject drugs. Persons who have used intranasal drugs. Persons deprived of liberty and previously incarcerated persons. Anyone with abnormal liver tests or liver disease. Students, health care workers, or members of public safety (e.g. correctional service officers or police) who have come into contact with blood at work through needlestick or sharps injuries. Anyone who has undergone hemodialysis. Persons who received transfusions in Colombia before 1996. Persons with comorbidities potentially associated with CH: diabetes, ischemic heart disease, cryoglobulinemia, chronic renal failure, Sjögren's syndrome, hypothyroidism, lichen planus, rheumatoid arthritis, HIV, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, waldenstrom's macroglobulinemia.\n\n* Individuals previously treated for HCV with sustained viral response in whom reinfection is suspected (individuals who continue to engage in risk behaviors)\n* Accept to participate in the study by signing the informed consent form.\n\nExclusion Criteria:\n\n* Have or have had hepatitis C with a proven cure by viral load at 12 weeks after the end of treatment without risk behaviors for reinfection.\n* Be on antiviral treatment against chronic hepatitis C virus.\n* That the patient voluntarily and consciously refuses to sign the informed consent form or is unable to give it due to any type of physical and\u002For mental disability.",{"count":188,"type":20},25669,"Introduction: Hepatitis C virus infection is a major cause of chronic hepatitis, cirrhosis, and liver cancer. The risk of developing cirrhosis for people with chronic infection with the virus ranges from 15% to 30% over a 20-year period. According to 2019 data from the World Health Organization there are 58 million people living with chronic hepatitis C infection. Three-quarters of those infected live in low- to middle-income countries, some of which lack budgets for screening, diagnosis and treatment campaigns. While good progress has been made in several countries, a significant gap in testing and treatment remains. Barriers to timely diagnosis include lack of awareness on the part of health professionals, availability and access to screening tests. Simplifying the cascade of care for this pathology would help ensure that more patients remain involved in the care pathway and ultimately achieve global goals.\n\nObjective: To estimate the prevalence of anti-HCV antibodies in patients with risk factors for hepatitis C virus captured by opportunity screening in the included hospital institutions.\n\nMethodology: Descriptive multicenter cross-sectional study. A total of 27160 participants among the seven institutions, 3880 per institution. Includes all persons over 18 years of age attended in the included health service provider institutions (IPS) who are users of hospitalization, emergency, outpatient and any other hospital care services. Application of a questionnaire to identify the inclusion criteria and data collection, signature of informed consent, sample collection by rapid test Abbott HCV rapid test - BIOLINE HCV and evaluation by tele-consultation by hepatologist principal investigator who will guide you to access the confirmatory test for HCV (viral load for Hepatitis C), the study will assume responsibility for its realization.",[26],[192,193],"prevalence","rapid diagnostic tests","2024-06-06",{"date":196,"type":38},"2024-06-10",{"date":198,"type":38},"2023-12-16",{"date":200,"type":20},"2024-12-31",{"name":178,"class":45}]